Ñî¹óåú´«Ã½Ò•îl

The FDA on Thursday approved rebisufligene etisparvovec (Fayuvi) as the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, the agency announced Thursday. (George, 9/18)

The FDA approved the Selution sustained limus release (SLR) drug-eluting balloon (DEB or DCB) to treat coronary in-stent restenosis (ISR), Cordis announced Monday. This makes Selution SLR the only sirolimus-based DEB available to treat an obstruction or narrowing of a stented vessel in patients with coronary artery disease. (Lou, 9/21)

A remote-controlled artificial urinary sphincter (AUS) has shown early promise for relieving urinary incontinence after prostate cancer surgery, while addressing one of the most awkward aspects of existing devices. (Bankhead, 9/20)

A quarter of patients with cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) presented before the age of 50 and had distinct features, including inherited genetic risk factors and type 2 diabetes, according to data from a prospective multicenter study. (Bassett, 9/17)

Getting your neck adjusted by a chiropractor does not appear to increase the risk of a rare but serious artery tear. Researchers analyzed data from more than 862,000 U.S. adults who sought care for a new episode of neck pain or headache between 2010 and 2025. (9/23)

The animals may help reveal the causes of brain disease in people and point the way to treatments. But researchers already are calling for new ethical guidelines. (Zimmer and Johnson, 9/16)